A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.

International journal of clinical pharmacology and therapeutics

Volumn 41, Issue 12, 2003, Pages 620-621

  Richly, H ^a   Kupsch, P ^a   Passage, K ^a   Grubert, M ^a   Hilger, R A ^a   Kredtke, S ^a   Voliotis, D ^a   Scheulen, M E ^a   Seeber, S ^a   Strumberg, D ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZENESULFONIC ACID DERIVATIVE; DOXORUBICIN; PYRIDINE DERIVATIVE; SORAFENIB;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; HUMAN; LIVER TUMOR; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BENZENESULFONATES; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; NEOPLASMS; PYRIDINES; TREATMENT OUTCOME;

EID: 1542437316     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41620     Document Type: Article

References (0)